Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer

NCT01516307 is registered in ClinicalTrials.gov with OBI Pharma, Inc as lead sponsor.

NCT NCT01516307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01516307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer
Lead sponsor
OBI Pharma, Inc
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
August 31, 2019
Enrollment
349 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer